3.91
0.00 (0.00%)
| Previous Close | 3.91 |
| Open | 3.96 |
| Volume | 10,630 |
| Avg. Volume (3M) | 34,926 |
| Market Cap | 41,696,492 |
| Price / Sales | 294.07 |
| Price / Book | 29.88 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Operating Margin (TTM) | -37,468.63% |
| Diluted EPS (TTM) | 3.38 |
| Quarterly Revenue Growth (YOY) | -51.70% |
| Quarterly Earnings Growth (YOY) | -19.50% |
| Total Debt/Equity (MRQ) | 26.43% |
| Current Ratio (MRQ) | 2.45 |
| Operating Cash Flow (TTM) | -19.88 M |
| Levered Free Cash Flow (TTM) | -11.33 M |
| Return on Assets (TTM) | -135.82% |
| Return on Equity (TTM) | -485.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Serina Therapeutics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | -5.0 |
| Price Volatility | 3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -1.40 |
|
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 63.85% |
| % Held by Institutions | 3.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Broadwood Capital Inc | 30 Sep 2025 | 83,195 |
| Waverly Advisors, Llc | 30 Sep 2025 | 67,492 |
| Linscomb Wealth, Inc. | 30 Sep 2025 | 18,800 |
| Keel Point, Llc | 30 Jun 2025 | 17,774 |
| Piscataqua Savings Bank | 30 Sep 2025 | 28 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MOREADITH RANDALL | - | 3.74 | -13,000 | -48,444 |
| Aggregate Net Quantity | -13,000 | |||
| Aggregate Net Value ($) | -48,444 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 3.74 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MOREADITH RANDALL | Officer | 03 Dec 2025 | Sell (-) | 5,000 | 3.48 | 17,400 |
| MOREADITH RANDALL | Officer | 03 Dec 2025 | Option execute | 5,000 | - | - |
| MOREADITH RANDALL | Officer | 02 Dec 2025 | Sell (-) | 1,500 | 3.81 | 5,715 |
| MOREADITH RANDALL | Officer | 02 Dec 2025 | Option execute | 1,500 | - | - |
| MOREADITH RANDALL | Officer | 25 Nov 2025 | Sell (-) | 5,965 | 3.91 | 23,323 |
| MOREADITH RANDALL | Officer | 25 Nov 2025 | Option execute | 5,965 | - | - |
| MOREADITH RANDALL | Officer | 24 Nov 2025 | Sell (-) | 535 | 3.75 | 2,006 |
| MOREADITH RANDALL | Officer | 24 Nov 2025 | Option execute | 535 | - | - |
| Date | Type | Details |
|---|---|---|
| 13 Nov 2025 | Announcement | Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights |
| 03 Nov 2025 | Announcement | Serina Therapeutics Provides Regulatory Update on SER-252 Program |
| 08 Oct 2025 | Announcement | Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors |
| 06 Oct 2025 | Announcement | Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease |
| 09 Sep 2025 | Announcement | Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease |
| 08 Sep 2025 | Announcement | Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |